Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding.
J Cyst Fibros
; 17(6): 779-782, 2018 11.
Article
in En
| MEDLINE
| ID: mdl-29866531
ABSTRACT
With the growing class of CFTR modulator therapy available to more patients and with increasing pregnancies in individuals with CF, there is a growing need to understand the effects of these agents during pregnancy. There are few reports of their continued use in the literature, although it is likely that this is not an uncommon occurrence. We report the uncomplicated and successful pregnancy of a woman treated with lumacaftor/ivacaftor, as well as the clinical course of the infant during the first 9â¯months of life. We also report drug levels in plasma from the mother, cord blood, breast milk, and infant to estimate fetal and infant drug exposure.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pregnancy Complications
/
Prenatal Exposure Delayed Effects
/
Quinolones
/
Cystic Fibrosis
/
Benzodioxoles
/
Aminophenols
/
Aminopyridines
/
Milk, Human
Type of study:
Diagnostic_studies
Language:
En
Journal:
J Cyst Fibros
Year:
2018
Document type:
Article